APOB and atherosclerosis: Schiopu et al. demonstrated that treatment with recombinant IgG anti-p45 (a peptide derived from the aldehyde-modified human apoB100) reduces the development of atherosclerosis in apoe−/− mice and potentiates plaque regression caused by cholesterol lowering in LDLr−/− mice [34].